Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion  (2026-02-23)
Gilead Sciences will pay as much as $7.8 billion to acquire partner Arcellx in ​its largest deal since 2020, the ​biopharma company said on ​Monday.